Substance / Medication

Tetrabenazine

Overview

Active Ingredient
tetrabenazine
RxNorm CUI
10390

Indications

Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington's disease.

Labeler: Golden State Medical Supply, Inc.Updated: 2025-10-13T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of tetrabenazine must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation o

Contraindications

When this intervention should not be used

Tetrabenazine tablets are contraindicated in patients: 5.1 [see Warnings and Precautions ()] Who are actively suicidal, or in patients with untreated or inadequately treated depression. 8.6 12.3 [see Use in Specific Populations (), Clinical Pharmacology ()] With hepatic impairment. 7.3 [see Drug Int

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.
Schneider Frank, Darpo Borje, Loupe Pippa S et al. · Clin Pharmacol Drug Dev · 2023
PMID: 36098670RCTFull text (PMC)
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
Hauser Robert A, Barkay Hadas, Wilhelm Amanda et al. · Parkinsonism Relat Disord · 2022
PMID: 35299070RCT
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Jankovic Joseph, Coffey Barbara, Claassen Daniel O et al. · JAMA Netw Open · 2021
PMID: 34609495RCTFull text (PMC)
Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression.
Zalsman Gil, Rehavi Moshe, Roz Netta et al. · J Neural Transm (Vienna) · 2011
PMID: 21484276RCT
Tourette's syndrome and role of tetrabenazine: review and personal experience.
Porta Mauro, Sassi Marco, Cavallazzi Mario et al. · Clin Drug Investig · 2008
PMID: 18544005RCT
GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine.
Meng Dong-Shuo, Li Guo-Jing, Sun Shen-Guo et al. · J Pharm Biomed Anal · 2025
PMID: 40081311Observational
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.
Frank Samuel, Testa Claudia M, Goldstein Jody et al. · CNS Drugs · 2025
PMID: 39825184ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tetrabenazine (substance)
SNOMED CT
363581004
UMLS CUI
C0039623
RxNorm CUI
10390
Labeler
Golden State Medical Supply, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.